SOLIGENIX, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price
SOLIGENIX, INC. (SNGX) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price of $1.64 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Share-Based Payment Arrangement › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice · last filed 2026-03-31
- SOLIGENIX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for the quarter ending 2021-03-31 was $1.75.
- SOLIGENIX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2025 was $1.64, a 51.04% decline from fiscal 2024.
- SOLIGENIX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2024 was $3.35, a 67.94% decline from fiscal 2023.
- SOLIGENIX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2023 was $10.45, a 18.08% increase from fiscal 2022.
- SOLIGENIX, INC. share-based compensation arrangements by share-based payment award, options, grants in period, weighted average exercise price for fiscal 2022 was $8.85, a 35.31% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price 12 month as first filed |
|---|---|---|---|---|---|
| 2025-12-31 | $1.64 10-K · filed 2026-03-31 | ||||
| 2024-12-31 | $3.35 10-K · filed 2026-03-31 | ||||
| 2023-12-31 | $10.45 10-K · filed 2025-03-21 | $0.65 10-K · filed 2024-03-15 | |||
| 2023-09-30 | $3.63 10-Q · filed 2023-11-13 | ||||
| 2023-06-30 | $3.63 10-Q · filed 2023-08-21 | ||||
| 2022-12-31 | $8.85 10-K · filed 2024-03-15 | ||||
| 2021-12-31 | $13.68 10-K · filed 2023-03-31 | $0.91 10-K · filed 2022-03-29 | |||
| 2021-09-30 | $1.63 10-Q · filed 2021-11-12 | ||||
| 2021-03-31 | $1.75 10-Q · filed 2021-08-13 | ||||
| 2020-12-31 | $2.17 10-K · filed 2022-03-29 | ||||
| 2019-12-31 | $1.09 10-K · filed 2021-03-30 | ||||
| 2017-12-31 | $1.54 10-K · filed 2018-03-15 | ||||
| 2016-12-31 | $3.90 10-K · filed 2018-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| Alzamend Neuro, Inc. (ALZN) | United States | $0.009B | |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| CNS Pharmaceuticals, Inc. (CNSP) | United States | $0.007B | |
| Acurx Pharmaceuticals, Inc. (ACXP) | United States | $0.007B | -0.97 |